Biden’s ‘Test to Treat’ Plan a Windfall for Pfizer, Merck — But Bad for Patients, Doctors Say • Children’s Health Defense

Share it with your friends Like

Thanks! Share it with your friends!

Close

“So they want to hand out two newly approved very costly Big Pharma drugs each with a laundry list of side effects and not nearly as effective as Ivermectin. Another windfall for Big Pharma at the expense of the taxpayer for no good reason, just pure greed.” Admin
 

The American Medical Association (AMA), in a press release on March 4, warned against the Biden administration’s test-to-treat plan saying the approach “flaunts patient safety and risks significant negative health outcomes.”

 

“The AMA is pleased the administration is ramping up supply of antivirals so in the near future they will be broadly available,” the organization said. “But, in the meantime, establishing pharmacy-based clinics as one-stop shopping for COVID-19 testing and treatments is extremely risky.”

 

The AMA said the plan was “well-intentioned” but claimed it oversimplified challenging prescribing decisions by “omitting knowledge of a patient’s medical history, the complexity of drug interactions and managing possible negative reactions.”

 

Read More: Biden’s ‘Test to Treat’ Plan a Windfall for Pfizer, Merck — But Bad for Patients, Doctors Say • Children’s Health Defense

  • Rating:
  • Views:214 views
  • Categories: Health